Tonix Pharmaceuticals Holding Corp. (TNXP)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$13.14-1.72%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · TNXP
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | 29.1 | 13.1 | 10.1 | 7.8 | — | — | — | — | — | — | — | — | — | — | — | — |
| Cost of Revenues | 4.7 | 6.6 | 7.8 | 4.7 | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Expenses & Income | ||||||||||||||||
| Selling, General & Admin | 126.0 | 87.7 | 40.1 | 34.8 | 30.2 | — | — | — | — | — | — | — | — | — | — | — |
| R&D Expenses | 63.9 | 44.5 | 40.0 | 86.7 | 81.9 | 68.8 | 36.2 | 18.2 | 17.6 | 13.3 | 28.5 | 35.5 | 18.6 | 4.7 | 2.6 | 1.2 |
| Operating Income | (165.4) | (125.7) | (136.7) | (118.4) | (112.1) | (92.3) | (50.5) | (28.8) | (26.3) | (21.3) | (39.0) | (48.2) | (27.7) | (10.9) | (6.7) | (3.4) |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | — | 0.1 | — | — | — | — | — | — | — | — | — | — | — | — | 0.0 | — |
| Interest & Investment Income | — | 4.1 | — | 1.7 | 1.9 | 0.0 | 0.0 | 0.2 | 0.2 | 0.2 | 0.1 | — | — | — | — | — |
| Asset Writedown | — | — | 59.0 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EBT, Incl. Unusual Items | — | — | — | — | — | — | — | — | — | (21.1) | (38.8) | (48.1) | (27.6) | — | — | — |
| Net Income | ||||||||||||||||
| Net Income | (159.7) | (124.0) | (130.0) | (116.7) | (110.2) | (92.3) | (50.5) | (28.6) | (26.1) | (21.1) | (38.8) | (48.1) | (27.6) | (10.9) | (9.5) | (3.5) |
| Per Share | ||||||||||||||||
| Basic EPS | (9.60) | (14.57) | (176.60) | — | (20.01) | (8.10) | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | (9.60) | (14.57) | (176.60) | — | (20.01) | (8.10) | — | — | — | — | — | — | — | — | — | — |
| Revenue per Share | 1.75 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 16.6 | 8.5 | 0.7 | 0.0 | 5.8 | 11.4 | — | — | — | — | — | — | — | — | — | — |
| Diluted Weighted Avg Shares | 16.6 | 8.5 | 0.7 | 0.0 | 5.8 | 11.4 | — | — | — | — | — | — | — | — | — | — |
| Supplemental | ||||||||||||||||
| EBITDA | — | (123.8) | (133.8) | (114.6) | (110.8) | (92.3) | (50.5) | (28.8) | (26.3) | (21.2) | (38.8) | (48.1) | — | — | — | — |
| EBIT | (165.4) | (125.7) | (136.7) | (118.4) | (112.1) | (92.3) | (50.5) | (28.8) | (26.3) | (21.3) | (39.0) | (48.2) | (27.7) | (10.9) | (6.7) | (3.4) |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.